MedTrace Logo

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

NCT02361086 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-02-01

No results posted yet for this study

Summary

The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of once-daily (QD) oral dosing of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).

Conditions

  • Castration-resistant Prostate Cancer
  • CRPC

Interventions

DRUG

VT-464: given orally once daily in 28 day cycles

VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.

Sponsors & Collaborators

  • Innocrin Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Joel Eisner · Innocrin Pharmaceutical

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-12-31
Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02361086 on ClinicalTrials.gov